- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Table of Contents
Case Reports in Critical Care
Volume 2013 (2013), Article ID 383125, 2 pages
Ketamine Infusion Associated with Improved Neurology in a Patient with NMDA Receptor Encephalitis
1Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, UK
2University of Edinburgh Medical School, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
Received 12 June 2013; Accepted 22 July 2013
Academic Editors: C. Diez, M. Egi, C. Mammina, A. J. Reddy, and K. S. Waxman
Copyright © 2013 Michael MacMahon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. Dalmau, E. Tüzün, H.-Y. Wu et al., “Paraneoplastic anti--methyl-D-aspartate receptor encephalitis associated with ovarian teratoma,” Annals of Neurology, vol. 61, no. 1, pp. 25–36, 2007.
- J. Dalmau, A. J. Gleichman, E. G. Hughes et al., “Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies,” The Lancet Neurology, vol. 7, no. 12, pp. 1091–1098, 2008.
- M. J. Titulaer, L. McCracken, I. Gabilondo, et al., “Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study,” The Lancet Neurology, vol. 12, no. 2, pp. 157–165, 2013.
- G. Davies, S. R. Irani, C. Coltart et al., “Anti--methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit,” Critical Care Medicine, vol. 38, no. 2, pp. 679–682, 2010.
- J. Burgdorf, X. Zhang, K. L. Nicholson, et al., “GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects,” Neuropsychopharmacology, vol. 38, no. 5, pp. 729–742, 2012.